Turp Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Transurethral Resection of the Prostate (TURP) is the gold-standard surgical procedure for treating benign prostatic hyperplasia (BPH) — a non-cancerous enlargement of the prostate gland that progressively restricts urine flow in aging men. During TURP, a urologist passes a resectoscope (a thin, lighted telescope fitted with a wire loop electrode) through the urethra and into the bladder, making no external skin incisions. The electrically charged loop excises obstructing prostate tissue in small segments, creating a wide channel that allows urine to flow freely.

First developed in the 1930s and continuously refined, TURP remains the benchmark against which all newer BPH surgical procedures are evaluated by international urology guidelines. Clinical evidence consistently documents dramatic improvements in the International Prostate Symptom Score (IPSS), peak urinary flow rate (Qmax), and patient-reported quality of life. Modern bipolar TURP technology, which uses isotonic saline irrigation instead of glycine, has substantially reduced the risk of electrolyte complications and made the procedure safer for elderly patients and those with cardiovascular comorbidities.

According to the European Association of Urology (EAU) and American Urological Association (AUA) guidelines, TURP is the recommended surgical treatment for men with symptomatic BPH and a prostate volume of approximately 30–80 mL who have not adequately responded to medical therapy, though experienced surgeons frequently extend this range.

TURP is performed primarily to relieve bladder outlet obstruction caused by an enlarged prostate. It effectively addresses a range of related urological conditions:

• Benign Prostatic Hyperplasia (BPH): The principal indication. BPH affects more than 50% of men in their 60s and up to 90% by age 85, causing lower urinary tract symptoms (LUTS) including weak stream, hesitancy, frequency, nocturia, urgency, and incomplete bladder emptying.
• Acute or Chronic Urinary Retention: When the bladder cannot empty without a catheter, TURP provides durable, long-term relief superior to ongoing catheterisation.
• Recurrent Urinary Tract Infections (UTIs): Residual post-void urine caused by outflow obstruction creates a bacterial reservoir; surgical deobstruction eliminates this risk factor.
• Bladder Stones: Calculi that form in retained urine within an inadequately emptying bladder are resolved when the underlying obstruction is corrected by TURP.
• Obstructive Nephropathy: Longstanding BPH causing hydronephrosis and declining kidney function requires urgent surgical intervention to preserve renal health.
• Recurrent Haematuria from BPH: Enlarged, highly vascular prostate tissue can rupture and bleed; resection removes the bleeding source definitively.

It is important to note that TURP is not a treatment for prostate cancer. However, all tissue removed during TURP is routinely submitted for histopathological analysis, and unsuspected prostate cancer is detected in approximately 10–15% of specimens — an important diagnostic benefit of the procedure.

Patient selection for TURP involves a comprehensive urological evaluation considering symptom severity, prostate size, overall medical fitness, and patient preference regarding side effects. Ideal candidates generally include:

• Moderate-to-severe BPH symptoms (IPSS > 8): Men whose lower urinary tract symptoms significantly impact quality of life and who have failed to respond adequately to alpha-blockers, 5-alpha reductase inhibitors, or combination medical therapy.
• Prostate volume 30–80 mL: TURP is most technically efficient in this range; larger glands may warrant HoLEP or open prostatectomy.
• Catheter-dependent urinary retention: Patients unable to void without catheterisation are priority surgical candidates.
• BPH-related complications: Bladder stones, diverticula, recurrent haematuria, or obstructive renal impairment attributable to BPH are strong indications for surgery.

Factors requiring careful assessment include:

• Active urinary tract infection: Must be eradicated with antibiotics before surgery to prevent bacteraemia.
• Anticoagulant therapy: Warfarin, newer oral anticoagulants, and antiplatelet agents increase bleeding risk; bridging strategies or timing around medication windows must be planned with the prescribing physician.
• Very small prostates (<30 mL): Medical therapy or minimally invasive options (Rezum, UroLift) may be preferable as TURP risks may outweigh benefits.
• Very large prostates (>100 mL): Operating time and fluid absorption risks increase substantially; HoLEP or open prostatectomy may offer safer alternatives.
• Desire to preserve fertility: Retrograde ejaculation affects 65–75% of TURP patients; men wishing to father children should consider alternatives or undergo sperm cryopreservation before surgery.

Pre-operative workup includes IPSS questionnaire, uroflowmetry, post-void residual ultrasound, PSA measurement, serum creatinine, and urinalysis. A flexible cystoscopy may be performed to assess urethral anatomy before proceeding.

All TURP procedures share the endoscopic transurethral approach, but important technical variants influence safety, effectiveness, and tissue availability for pathology:

Monopolar TURP (Classic Technique)

The original technique employing a monopolar electrical current and hypotonic glycine irrigation fluid. Highly effective with decades of evidence, but carries a small risk of TURP syndrome (dilutional hyponatraemia) from systemic absorption of the hypotonic irrigant, particularly in prolonged cases. Strict fluid balance monitoring limits this risk. Most urology departments worldwide are trained in this technique.

Bipolar TURP (Preferred Modern Standard)

Uses normal saline (0.9% NaCl, isotonic) as the irrigant and contains the electrical circuit entirely within the resectoscope tip. This design eliminates the risk of TURP syndrome entirely. Multiple randomised controlled trials and systematic reviews confirm that bipolar TURP is equivalent to monopolar TURP in efficacy while demonstrating a significantly improved safety profile — lower complication rates, less haemorrhage, and shorter catheterisation times. Bipolar TURP is now the preferred technique at high-volume urology centres.

Photoselective Vaporisation of the Prostate (GreenLight Laser)

A laser-based conceptual variant: a high-powered (120–180W) KTP or LBO laser vaporises prostate tissue with haemostatic precision. Preferred for patients on anticoagulant therapy due to superior haemostasis. Key limitation: no tissue is available for histological analysis.

Step-by-Step Procedural Overview

The patient receives spinal (preferred) or general anaesthesia. The resectoscope is introduced through the urethra under continuous saline irrigation and direct vision. The surgeon identifies the obstructing prostate adenoma and resects it systematically from the apex toward the bladder neck using the cutting loop, while simultaneously coagulating bleeding vessels. Resected tissue chips are evacuated from the bladder with an Ellik evacuator. A 20–24Fr three-way Foley catheter is placed for 24–48 hours. Total operative time ranges from 45 to 90 minutes depending on prostate volume. All resected chips are sent for histopathology.

TURP is supported by the most extensive evidence base of any BPH surgical treatment and delivers the following well-documented benefits:

• Substantial and durable symptom relief: Clinical studies and long-term follow-up data consistently show that 85–90% of patients achieve meaningful improvement in IPSS scores after TURP, with benefits maintained at 10–15 years in the majority of cases.
• Dramatically improved urinary flow rate: Peak urinary flow (Qmax) typically increases from under 10 mL/second pre-operatively to over 20 mL/second within weeks of surgery — often more than doubling flow.
• Freedom from catheterisation: Over 90% of patients with catheter-dependent urinary retention achieve spontaneous voiding after TURP.
• Diagnostic tissue yield: Unlike minimally invasive procedures (Rezum, UroLift) and laser vaporisation, TURP provides a histological specimen that allows detection of unsuspected prostate cancer in approximately 10–15% of patients — a potentially life-saving diagnostic bonus.
• Cost-effectiveness over lifetime: As a single, definitive surgical procedure, TURP avoids years of monthly medication costs and has lower long-term retreatment rates than most minimally invasive alternatives, making it cost-effective from a healthcare economics perspective.
• Shorter hospitalisation than open surgery: The absence of external incisions means hospital stays of 1–3 days versus 5–7 days for open prostatectomy, with correspondingly faster overall recovery.
• Well-characterised safety profile: Decades of global clinical experience mean complication types and rates are well understood, manageable, and continuing to decline as bipolar technique adoption increases.

As with any surgical procedure, TURP carries inherent risks that patients must understand before consenting. A frank discussion with the treating urologist is essential.

Common Complications

• Retrograde Ejaculation: The most frequent long-term effect, occurring in 65–75% of patients. During orgasm, semen passes backward into the bladder rather than being expelled forward. The sensation of orgasm is preserved. While medically harmless (semen passes out with urine), it causes infertility without assisted reproduction. Men who wish to father children should strongly consider alternatives or bank sperm before TURP.
• Transient Urinary Incontinence: Mild stress incontinence and urgency are common immediately after catheter removal as the urethra heals. Persistent, significant incontinence is uncommon (<1% with intact sphincter technique) and usually resolves with pelvic floor exercises.
• Urinary Tract Infection (UTI): Affects 5–10% of patients post-operatively; managed with a short antibiotic course.

Serious but Less Common Risks

• Significant bleeding requiring transfusion: Occurs in 1–3% of cases; risk increases with very large prostates, prolonged operating time, or anticoagulant use.
• TURP Syndrome (monopolar technique only): Systemic absorption of glycine irrigant causes dilutional hyponatraemia. Symptoms range from nausea and agitation to, in severe cases, cerebral oedema and cardiovascular compromise. Risk is eliminated entirely with bipolar technique.
• Urethral Stricture: Scar tissue forming in the urethra at the catheter or resectoscope entry site occurs in approximately 3–5% of patients, typically becoming apparent months to years post-operatively. Treatment involves urethral dilation or optical urethrotomy.
• Bladder Neck Stenosis: Fibrosis at the bladder neck requires reoperation (bladder neck incision) in 1–2% of cases.
• Erectile Dysfunction: Reported in 5–10% of patients, though establishing direct causality vs. pre-existing age-related ED is difficult. Risk is lower with bipolar technique and meticulous preservation of the external sphincter.

Permanent severe urinary incontinence and sphincter damage are rare (<1%) with experienced surgeons. Selecting a urologist who performs more than 50 TURP procedures annually at an accredited centre substantially reduces the likelihood of complications.

Recovery from TURP follows a predictable trajectory and most patients report progressive improvement over 4–6 weeks.

Immediate Post-Operative Period (Hospital: Days 1–3)

A three-way Foley catheter remains in situ for 24–48 hours, allowing continuous bladder irrigation with saline to prevent blood clot formation. Patients are encouraged to drink 2–3 litres of fluid per day. Mild pelvic discomfort and bladder spasms are managed with oral analgesics and anticholinergic medications. Most patients mobilise on the day of surgery and are discharged when the urine clears and normal voiding is re-established after catheter removal.

First Two Weeks at Home

After catheter removal, urinary flow typically improves dramatically. However, some temporary urgency, increased frequency, and a mild burning sensation during urination are expected as the urethra and resection site heal. Intermittent pink-tinged or lightly blood-stained urine is normal. Patients should avoid strenuous lifting (>5 kg), sexual activity, constipation (straining increases bleeding risk), and driving for the first 2 weeks. Return to sedentary work is usually possible within 1–2 weeks.

Weeks 3–6

Most patients resume non-strenuous activities including gentle walking and light exercise. A transient recurrence of haematuria around days 14–21 post-operatively, when the eschar over the resection bed separates, is anticipated and normal — patients should rest, increase fluid intake, and contact their surgeon if bleeding is heavy or accompanied by clots causing retention.

Follow-Up Assessments

A post-operative clinic review at 4–6 weeks includes uroflowmetry and post-void residual ultrasound to objectively confirm deobstruction. PSA levels are rechecked at 3 months; a persistently elevated or rising PSA after TURP warrants further evaluation for concurrent prostate cancer. Annual check-ups thereafter monitor for urethral stricture, bladder neck stenosis, or symptom recurrence from regrowth of residual adenoma.

The cost of TURP varies considerably depending on geographic location, healthcare system, hospital type, technique used, and insurance coverage.

Key Drivers of Cost

• Country and Healthcare System: TURP is generally covered under national health schemes (NHS England, Australia Medicare, Canadian provincial health). In the United States, out-of-pocket costs without insurance range from USD 10,000–25,000 inclusive of surgeon fees, anaesthesia, hospital stay, and pathology. In India, accredited hospitals offer TURP at USD 1,500–4,000. Thailand, Turkey, and Malaysia price the procedure between USD 2,000–5,000.
• Hospital Type and Accreditation: Private hospitals charge significantly more than public institutions. JCI-accredited international hospitals may carry a premium but offer internationally trained surgeons, advanced equipment, and structured patient safety protocols.
• Technique Used: Bipolar TURP or GreenLight laser PVP may carry a modest cost premium over standard monopolar TURP due to capital equipment and disposable costs.
• Anaesthesia: Spinal anaesthesia is generally less expensive than general anaesthesia and is associated with fewer post-operative respiratory complications in older patients.
• Prostate Size: Larger prostates require longer operative time, more disposables, and occasionally a planned two-stage approach — all of which increase total cost.
• Histopathology: Laboratory analysis of resected tissue adds to total cost but is clinically non-negotiable and may detect cancer, altering long-term management.

Medical tourism for TURP is popular from Western Europe, North America, and Australia to India, Thailand, and Turkey, where patients can achieve savings of 60–80% while receiving care at internationally accredited facilities. Patients considering this route should confirm that the chosen hospital has a dedicated histopathology service and documented protocols for managing TURP complications including TURP syndrome and significant haemorrhage.

Depending on prostate size, symptom severity, age, fertility intentions, and patient preference, several well-validated alternatives to TURP are available:

Medical Management

• Alpha-1 Adrenergic Blockers (tamsulosin, alfuzosin, silodosin, terazosin): Relax smooth muscle in the prostate and bladder neck, improving urinary flow within days. First-line therapy for most men with mild-to-moderate BPH. Do not reduce prostate volume. Side effects include dizziness and retrograde ejaculation (particularly silodosin).
• 5-Alpha Reductase Inhibitors (5-ARIs) (finasteride, dutasteride): Reduce prostate volume by 20–30% over 3–6 months by blocking DHT-mediated glandular growth. Most effective in larger prostates (>40 mL) and in men with elevated PSA. Combination therapy (alpha-blocker + 5-ARI) is superior to monotherapy for moderate-severe symptoms in large prostates.
• Tadalafil (PDE5 inhibitor): FDA-approved for BPH; also benefits concurrent erectile dysfunction. Mechanism involves relaxation of smooth muscle in the prostate and bladder.

Minimally Invasive Surgical Therapies (MISTs)

• UroLift (Prostatic Urethral Lift): Small permanent implants mechanically retract and hold obstructing lateral lobes apart. Key advantages: preserves antegrade ejaculation, office-based or outpatient procedure, rapid recovery. Best suited for prostates under 80 mL without a prominent median lobe. Less durable than TURP at long-term follow-up.
• Rezum Water Vapour Therapy: Convective water vapour (steam) injected into prostatic tissue ablates obstructing cells via thermal energy. Preserves ejaculation in most patients. Suitable for prostates 30–80 mL. Performed in an office setting under local anaesthesia.
• Transurethral Microwave Thermotherapy (TUMT): Microwave energy heats and destroys obstructing prostate tissue. Less effective than TURP but avoids general or spinal anaesthesia.

Laser Surgical Alternatives

• HoLEP (Holmium Laser Enucleation of the Prostate): Considered by many urologists to be superior to TURP for large prostates (>80 mL). The holmium laser enucleates the entire adenoma, which is then morcellated. Provides tissue for histology. Lower bleeding risk, shorter catheter time, equally durable outcomes. Requires specialised training and equipment. Increasingly available globally.
• GreenLight Laser PVP (Photoselective Vaporisation): Preferred for anticoagulated patients or those with high anaesthetic risk. Good haemostasis; no tissue specimen.

Open and Robotic Prostatectomy

Simple (non-cancer) open transvesical or retropubic prostatectomy is reserved for prostates typically exceeding 100 mL where endoscopic access is impractical. Robotic-assisted simple prostatectomy offers reduced blood loss and hospital stay compared to open surgery with equivalent functional outcomes.